MIFH
NTLA icon

Migdal Insurance & Financial Holdings’s Intellia Therapeutics NTLA Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,800
Closed -$1.27M – 645
2021
Q1 		$1.27M Buy
15,800
+9,805
+164% +$658K 0.01% 224
2020
Q4 		$326K Buy
+5,995
New +$218K ﹤0.01% 249

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Migdal Insurance & Financial Holdings's NTLA Position: Q2 2021 in Review

Migdal Insurance & Financial Holdings sold out of Intellia Therapeutics (NTLA) in Q2 2021, closing a stake of 15,800 shares — an estimated $1.27M sold.

Migdal Insurance & Financial Holdings first reported a position in NTLA in Q4 2020 and held it in 2 quarters. The position peaked at $1.27M in Q1 2021. 336 funds tracked by Wall St. Rank hold NTLA as of Q2 2021.

  • Migdal Insurance & Financial Holdings reported no remaining Intellia Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 15,800 Intellia Therapeutics shares in Q2 2021, an estimated $1.27M.
  • Migdal Insurance & Financial Holdings first reported a position in Intellia Therapeutics in Q4 2020 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Intellia Therapeutics position peaked at $1.27M in Q1 2021.
  • 336 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2021.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q2 2021, filed 4 Aug 2021.